Skip to main content

PLRX

Stock
Health Care
Biotechnology

Performance overview

PLRX Price
Price Chart

Forward-looking statistics

Beta
1.14
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Company info

SectorHealth Care
IndustryBiotechnology
Employees160
Market cap$672.6M

Fundamentals

Enterprise value-$174.3M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity23.40

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.61
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$4M
Put-call ratio

Macro factor sensitivity

Growth-4.2
Credit+10.4
Liquidity+1.5
Inflation-7.3
Commodities-2.0
Interest Rates-0.3

Valuation

Dividend yield0.00%
PEG Ratio-0.31
Price to sales
P/E Ratio-0.31
Enterprise Value to Revenue
Price to book0.30

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day
Ex. dividend day

News

PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know

PLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (April 10, 2025)
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

On Monday, Pliant Therapeutics Inc. PLRX announced that it would discontinue the BEACON-IPF Phase 2b trial, which evaluated bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).

Benzinga (March 3, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free